Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer

X
Trial Profile

MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab (Primary) ; Tucatinib (Primary)
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms MOUNTAINEER
  • Sponsors Seagen
  • Most Recent Events

    • 09 Nov 2023 Status changed from active, no longer recruiting to completed.
    • 24 Oct 2023 Results of exploratory analysis assessing the impact of concomitant baseline genomic alterations on the clinical activity of tucatinib plus trastuzumab, presented at the 48th European Society for Medical Oncology Congress.
    • 16 Oct 2023 According to Astellas media release, data from this study will be presented at the European Society for Medical Oncology (ESMO) Congress 2023 from October 20-24.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top